CL2014001236A1 - Uso de una composicion que comprende un compuesto contra el receptor de egf y un compuesto contra el gangliosido neugcgm3 para tratar cancer; y kit utilizado que comprende dichos compuestos. - Google Patents

Uso de una composicion que comprende un compuesto contra el receptor de egf y un compuesto contra el gangliosido neugcgm3 para tratar cancer; y kit utilizado que comprende dichos compuestos.

Info

Publication number: CL2014001236A1
Authority: CL; Chile
Prior art keywords: compound against; compounds; composition; treat cancer; egf receptor
Prior art date: 2011-12-27

Application number

CL2014001236A

Other languages

English (en)

Inventor

Palomo Adys Gonzalez

Perez Adriana Carr

Monzon Kalet Leon

Santana Rances Blanco

Alvarez Maria Del Carmen Barroso

Abraham Amparo Emilia Macias

Casimiro Jose Enrique Montero

Original Assignee

Centro Inmunologia Molecular

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2011-12-27

Filing date

2014-05-12

Publication date

2014-08-08

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47435671&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2014001236(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2014-05-12 Application filed by Centro Inmunologia Molecular filed Critical Centro Inmunologia Molecular

2014-08-08 Publication of CL2014001236A1 publication Critical patent/CL2014001236A1/es

Links

150000001875 compounds Chemical class 0.000 title 3
102000001301 EGF receptor Human genes 0.000 title 1
108060006698 EGF receptor Proteins 0.000 title 1
206010028980 Neoplasm Diseases 0.000 title 1
201000011510 cancer Diseases 0.000 title 1
150000002270 gangliosides Chemical class 0.000 title 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001102—Receptors, cell surface antigens or cell surface determinants
- A61K39/001103—Receptors for growth factors
- A61K39/001104—Epidermal growth factor receptors [EGFR]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001169—Tumor associated carbohydrates
- A61K39/001171—Gangliosides, e.g. GM2, GD2 or GD3
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3076—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties
- C07K16/3084—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties against tumour-associated gangliosides
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
- C07K16/4208—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig
- C07K16/4241—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig
- C07K16/4258—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig against anti-receptor Ig
- C07K16/4266—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig against anti-receptor Ig against anti-tumor receptor Ig
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Immunology (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Mycology (AREA)
Microbiology (AREA)
Engineering & Computer Science (AREA)
Molecular Biology (AREA)
Oncology (AREA)
Bioinformatics & Cheminformatics (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Genetics & Genomics (AREA)
Biophysics (AREA)
Biochemistry (AREA)
Cell Biology (AREA)
Biomedical Technology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Dermatology (AREA)
Endocrinology (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

CL2014001236A 2011-12-27 2014-05-12 Uso de una composicion que comprende un compuesto contra el receptor de egf y un compuesto contra el gangliosido neugcgm3 para tratar cancer; y kit utilizado que comprende dichos compuestos. CL2014001236A1 (es)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
CU20110245A CU24070B1 (es)	2011-12-27	2011-12-27	Composiciones farmacéuticas para el tratamiento de tumores que expresan regf y gangliósidos n-glicolilados gm3 (neugcgm3)

Publications (1)

Publication Number	Publication Date
CL2014001236A1 true CL2014001236A1 (es)	2014-08-08

Family

ID=47435671

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CL2014001236A CL2014001236A1 (es)	2011-12-27	2014-05-12	Uso de una composicion que comprende un compuesto contra el receptor de egf y un compuesto contra el gangliosido neugcgm3 para tratar cancer; y kit utilizado que comprende dichos compuestos.

Country Status (26)

Country	Link
US (1)	US9790279B2 (es)
EP (1)	EP2805747B1 (es)
JP (1)	JP6027137B2 (es)
KR (1)	KR101703637B1 (es)
CN (1)	CN103998098B (es)
AR (1)	AR089490A1 (es)
AU (1)	AU2012361321C1 (es)
BR (1)	BR112014015693B1 (es)
CA (1)	CA2855182C (es)
CL (1)	CL2014001236A1 (es)
CO (1)	CO6990729A2 (es)
CU (1)	CU24070B1 (es)
EA (1)	EA030346B1 (es)
ES (1)	ES2694324T3 (es)
IL (1)	IL233323B (es)
MX (1)	MX359476B (es)
MY (1)	MY185138A (es)
PE (1)	PE20142328A1 (es)
PH (1)	PH12014501202A1 (es)
SG (1)	SG11201403014XA (es)
TN (1)	TN2014000203A1 (es)
TR (1)	TR201816232T4 (es)
TW (1)	TWI523663B (es)
UA (1)	UA111403C2 (es)
WO (1)	WO2013097834A1 (es)
ZA (1)	ZA201405424B (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CU20170173A7 (es) *	2017-12-27	2019-11-04	Ct Inmunologia Molecular	Nano-partículas que contienen el gangliósido gm3 como inmunomoduladoras

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP0586002B1 (en) *	1992-08-18	2000-01-19	CENTRO de IMMUNOLOGIA MOLECULAR	Monoclonal antibodies recognizing the epidermal growth factor receptor, cells and methods for their production and compositions containing them
CN1103404A (zh) *	1993-03-01	1995-06-07	分子免疫中心	识别表皮生长因子受体的新的单克隆抗体，生产这种抗体的细胞和方法以含有这种抗体的组合物
CU22420A1 (es) *	1993-12-29	1996-01-31	Centro Inmunologia Molecular	Composicion vacunal para el desarrollo de una respuesta contra gangliosidos n glicolilados y su uso para el tratamiento del cancer
CU22731A1 (es)	1998-02-05	2002-02-28	Centro Inmunologia Molecular	Anticuerpo monoclonal que reconoce el oligosacárido ácido siálico n´glicolilado-galactosa-glucosa (ngcneu-gal-glu) en tumores malignos y composiciones farmacéuticas que los contienen
PE20020572A1 (es) *	2000-12-06	2002-07-31	Centro Inmunologia Molecular	Preparaciones para potenciar la inmunogenicidad de antigenos poco inmunogenicos
CU23007A1 (es) *	2001-04-06	2004-12-17	Ct De Inmunologia Molecular Ct De Inmunologia Mole	Combinaciones inmunoterapéuticas para el tratamiencombinaciones inmunoterapéuticas para el tratamiento de tumores que sobre-expresan gangliósidos to de tumores que sobre-expresan gangliósidos
CU23403A1 (es) *	2003-04-23	2009-08-04	Centro Inmunologia Molecular	Anticuerpos recombinantes y fragmentos que reconocen el gangliósido n-glicolil gm3 y su uso para diagnóstico y tratamiento de tumores

2011
- 2011-12-27 CU CU20110245A patent/CU24070B1/es active IP Right Grant
2012
- 2012-04-12 UA UAA201408435A patent/UA111403C2/uk unknown
- 2012-12-04 JP JP2014549356A patent/JP6027137B2/ja active Active
- 2012-12-04 BR BR112014015693-0A patent/BR112014015693B1/pt active IP Right Grant
- 2012-12-04 KR KR1020147017242A patent/KR101703637B1/ko active IP Right Grant
- 2012-12-04 AU AU2012361321A patent/AU2012361321C1/en active Active
- 2012-12-04 SG SG11201403014XA patent/SG11201403014XA/en unknown
- 2012-12-04 PE PE2014001031A patent/PE20142328A1/es not_active Application Discontinuation
- 2012-12-04 MX MX2014007919A patent/MX359476B/es active IP Right Grant
- 2012-12-04 WO PCT/CU2012/000007 patent/WO2013097834A1/es active Application Filing
- 2012-12-04 CN CN201280062315.8A patent/CN103998098B/zh active Active
- 2012-12-04 CA CA2855182A patent/CA2855182C/en active Active
- 2012-12-04 MY MYPI2014701762A patent/MY185138A/en unknown
- 2012-12-04 ES ES12806334.4T patent/ES2694324T3/es active Active
- 2012-12-04 TR TR2018/16232T patent/TR201816232T4/tr unknown
- 2012-12-04 US US14/369,435 patent/US9790279B2/en active Active
- 2012-12-04 EP EP12806334.4A patent/EP2805747B1/en active Active
- 2012-12-04 EA EA201491284A patent/EA030346B1/ru not_active IP Right Cessation
- 2012-12-11 TW TW101146617A patent/TWI523663B/zh active
- 2012-12-27 AR ARP120105011 patent/AR089490A1/es unknown
2014
- 2014-05-06 TN TNP2014000203A patent/TN2014000203A1/en unknown
- 2014-05-12 CL CL2014001236A patent/CL2014001236A1/es unknown
- 2014-05-28 PH PH12014501202A patent/PH12014501202A1/en unknown
- 2014-06-20 CO CO14134694A patent/CO6990729A2/es unknown
- 2014-06-23 IL IL233323A patent/IL233323B/en active IP Right Grant
- 2014-07-23 ZA ZA2014/05424A patent/ZA201405424B/en unknown

Also Published As

Publication number	Publication date
UA111403C2 (uk)	2016-04-25
AU2012361321B2 (en)	2015-11-19
CU24070B1 (es)	2015-01-29
TN2014000203A1 (en)	2015-09-30
CN103998098B (zh)	2017-08-04
AU2012361321A8 (en)	2014-08-07
IL233323A0 (en)	2014-08-31
CU20110245A7 (es)	2013-08-29
MX359476B (es)	2018-09-27
EP2805747B1 (en)	2018-10-17
TWI523663B (zh)	2016-03-01
US20140363494A1 (en)	2014-12-11
WO2013097834A1 (es)	2013-07-04
KR101703637B1 (ko)	2017-02-07
SG11201403014XA (en)	2014-09-26
EA030346B1 (ru)	2018-07-31
MX2014007919A (es)	2014-07-30
ES2694324T3 (es)	2018-12-19
CA2855182A1 (en)	2013-07-04
CA2855182C (en)	2018-06-12
AU2012361321A1 (en)	2014-07-24
BR112014015693A2 (pt)	2017-06-13
NZ627012A (en)	2016-01-29
IL233323B (en)	2018-11-29
JP2015506354A (ja)	2015-03-02
KR20140100538A (ko)	2014-08-14
AU2012361321C1 (en)	2016-03-10
BR112014015693A8 (pt)	2017-07-04
ZA201405424B (en)	2016-02-24
TR201816232T4 (tr)	2018-11-21
CO6990729A2 (es)	2014-07-10
AR089490A1 (es)	2014-08-27
EA201491284A1 (ru)	2014-09-30
MY185138A (en)	2021-04-30
US9790279B2 (en)	2017-10-17
EP2805747A1 (en)	2014-11-26
TW201336509A (zh)	2013-09-16
CN103998098A (zh)	2014-08-20
BR112014015693B1 (pt)	2023-03-21
JP6027137B2 (ja)	2016-11-16
PH12014501202A1 (en)	2014-09-08
PE20142328A1 (es)	2015-01-29

Publication	Publication Date	Title
BR112014001255A2 (pt)	2017-02-21	composto, uso de um composto, combinação, e, composição farmacêutica
CL2013001947A1 (es)	2014-05-23	Composicion farmaceutica que comprende pioglitazona; uso de pioglitazona para tratar alzheimer; composicion que comprende pioglitazona.
CL2014002750A1 (es)	2015-04-06	Anticuerpo aislado o fragmento que se enlaza a un estado inactiva de un receptor her; composición farmacéutica que lo comprende; uso del anticuerpo para tratar cancer
BR112014013760A2 (pt)	2017-06-13	composto, composição farmacêutica e uso de um composto
CL2014001065A1 (es)	2014-07-25	Compuestos derivados de piridopirazinas; composicion farmaceutica que los comprende; y su uso para la prevencion o el tratamiento de un estado patologico o afeccion mediada por una fgfr cinasa tal como cancer.
CL2014001291A1 (es)	2014-09-26	Agentes de iarn de doble hebra; composiciones y metodos de uso de los mismos para tratar enfermedades asociadas con transtiretina (ttr).
BR112016000489A2 (pt)	2017-07-25	composto, composição farmacêutica que o compreende, uso da composição e métodos para fabricar compostos
BR112014029530A2 (pt)	2017-06-27	compostos, composição farmacêutica e uso de um composto
BR112014000260A2 (pt)	2017-03-01	composto, e, uso de um composto
CL2008000340A1 (es)	2008-08-08	Compuestos derivados de ditiocarbamatos; su procedimiento de preparacion; composicion colectora que los contiene; y metodos para el beneficio de una mena mineral que comprende su uso como colectores de espuma de flotacion.
BR112014005669A2 (pt)	2017-04-04	composto, composição farmacêutica e uso de um composto
CL2011002595A1 (es)	2013-10-04	Uso de una combinacion de un agente anticancerigeno y un antioxidante para tratar el cancer; y compicicion farmaceutica que comprende dicha combinacion.
BR112014003567A2 (pt)	2018-08-14	composto, uso de um composto, e, composição farmacêutica
BR112013031813A2 (pt)	2016-12-13	composição para aplicação tópica
BR112013030302A2 (pt)	2017-06-27	composto, composição farmacêutica, uso de um composto, combinação de um composto e dispositivo
CO6811867A2 (es)	2013-12-16	Cannabinoides para uso en el tratamiento del dolor neuropático
BR112014009471A2 (pt)	2017-04-18	compostos, combinação de um composto, composição farmacêutica, uso de um composto, dispositivo e kit
BRPI0914069A2 (pt)	2016-09-27	composição de vacina para uso contra o influenza
BR112014013177A2 (pt)	2017-06-13	composto, composição farmacêutica e uso de um composto
BR112014016635A2 (pt)	2017-06-13	composto, composição, e, uso de um composto
BR112014013213A2 (pt)	2017-06-13	composição microbicida, método para fornecer um efeito bactericida a um substrato e uso de uma composição
CL2014003059A1 (es)	2015-03-06	Uso de seaprose para eliminar biopelículas bacterianas; composicion de seaprose.
BR112013029206A2 (pt)	2017-02-14	composto, e, uso de um composto
BR112014013178A2 (pt)	2017-06-13	composto, composição farmacêutica e uso de um composto
CL2013000734A1 (es)	2013-11-08	Uso de una composicion que comprende compuestos derivados de 1-h-imidazol-4-il sustituido para bajar la presion intraocular; kit farmaceutico.